AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
Oracle is expanding layoffs but its new CFO says “don’t do more with less”
4
The ThinkPad X13 is almost boring, and that’s exactly the point
5
Buildots raises $130 million at nearly $1 billion valuation as AI boom drives data center construction
More news

Pharma

20 stories about Pharma
המרכז הלוגיסטי של חברת טבע בשוהם

Teva reaches its highest level since 2017 as investors embrace its transformation

23.08.26|CTech
Shares have risen about 20% in August, lifting the Israeli drugmaker's market value to $43.5 billion as innovative medicines and a growing pipeline reshape its investment story.
בניין חברת טבע כפר סבא

Teva's Israeli identity becomes a courtroom issue in U.S. price-fixing trial

13.08.26|Reuters, CTech
Humana agreed not to refer to Teva as an Israeli company during arguments or questioning after the drugmaker raised concerns about potential jury bias.
קלוד של אנתרופיק לצד מנכ"ל החברה דריו אמודיי

Anthropic wants to disrupt drug discovery. Industry experts say the real challenge comes later

12.07.26|Omer Kabir
The AI company is entering pharmaceuticals with ambitions to accelerate medicine development, but scientists argue the real challenge is proving drugs work in humans. 
בניין חברת טבע כפר סבא

Teva to cut 250 jobs in API division as sale talks stall

10.06.26|Sophie Shulman
Pharmaceutical giant restructures raw materials unit amid stalled revenues and strategic review. 
Remepy founders

Merck KGaA and Remepy partner to test ‘Hybrid Drugs’ model

28.04.26|Meir Orbach
Collaboration explores combining medication with app-based therapies in rare tumor programs. 
המרכז הלוגיסטי של חברת טבע בשוהם

Teva bets on vitiligo drug in deal worth up to $500 million

12.01.26|Sophie Shulman
Agreement with Royalty Pharma underscores shift toward branded medicines.
כנס ניו יורק - ד"ר רביב פרילוק מנכ"ל PhaseV

PhaseV raises $50 million Series A to rethink how drugs get to market

13.05.25|CTech
With over 30 global customers, the AI startup targets inefficiencies in clinical trials. 
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
קופקסון זריקה תרופה טבע

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman
Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug. 
מטה אלי לילי ב אינדיאנפוליס

1,000% stock increase: The story behind Eli Lilly’s pharmaceutical dominance

14.08.24|Viki Auslender
Beating second-quarter forecasts mainly due to its weight loss and diabetes drugs, Eli Lilly, the company aspiring to be worth a trillion dollars, has invested heavily in innovative developments, becoming the pharmaceutical manufacturer with the highest market value in the world.
מניית טבע בורסת ניו יורק מניה

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach
The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters
"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis
ד״ר צחון בנטואיץ׳ מייסד משותף של קיוריס Quris AI

Pharma giant Merck expands collaboration with Quris-AI

28.09.23|Meir Orbach
This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva profit plummets, stock slides

10.05.23|Reuters
Teva plans to unveil a new strategy next week which CEO Francis said would "build on Teva's strong foundations, key strengths, and sets the stage for long-term growth"
וירוס וירוסים חיידק חיידקים בקטריות

Biomica raises $20 million for microbiome-based therapeutics

22.12.22|CTech
The Israeli company's drug candidates are based on a rationally designed consortia of microbes, selected through high-resolution functional microbiome analysis
מוח Brain Medtech

New treatment aiming to reduce suicidality in Bipolar Disorder

28.11.22|James Spiro
American-Israeli company NRx is currently undergoing a trial that combines two kinds of compounds hoping to reduce the negative side effects of current medicine
BioRaptor Team

“People working on technologies for humanity should have the best tools possible”

27.11.22|CTech
BioRaptor recently raised $3 million in Seed to generate actionable scientist-friendly insights
תמונה קבוצתית עובדי סקופיו

Scopio Labs raises $50 million Series C for digital microscope

09.02.22|Meir Orbach
The Israeli company's device creates new information that was not available until now thanks to the development of advanced computational photography technology that allows for the first time a fast scan of large surfaces at the highest resolution in the world
שי פוליקר מנכל MEDX Xelerator

U.S. pharma giant West to invest in Israeli incubator MEDX Xelerator

21.11.21|CTech
"Israel is well known as one of the world’s centers of medical innovation and MEDX’s senior management has a proven track record," said Scott Young, VP of Research at West
More Articles